知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.013 seconds)

    HIGH DOSAGE TEBIPENEM PIVOXIL TABLET FORMULATION
    2.
    发明申请
    HIGH DOSAGE TEBIPENEM PIVOXIL TABLET FORMULATION 有权

    公开(公告)号：US20250049766A1

    公开(公告)日：2025-02-13

    申请号：US18665330

    申请日：2024-05-15

    Applicant: Spero Therapeutics, Inc.

    Inventor： Akash Jain ,  Ching-Kuo Jim Chow

    IPC: A61K31/427 ,  A61K9/20 ,  A61P31/04

    Abstract: The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w/w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w/w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w/w tebipenem pivoxil HBr, 5-25% w/w of a diluent, 0.5 to 5% w/w of a glidant, 0.5 to 5% w/w of a lubricant, and optionally 0.5 to 5% w/w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.

    High dosage tebipenem pivoxil tablet formulation
    5.
    发明授权
    High dosage tebipenem pivoxil tablet formulation 有权

    公开(公告)号：US12048691B2

    公开(公告)日：2024-07-30

    申请号：US17525619

    申请日：2021-11-12

    Applicant: SPERO THERAPEUTICS, INC.

    Inventor： Akash Jain ,  Ching-Kuo Jim Chow

    IPC: A61K9/20 ,  A61K31/427 ,  A61P31/04

    CPC classification number: A61K31/427 ,  A61K9/2009 ,  A61K9/2027 ,  A61K9/2054 ,  A61P31/04

    Abstract: The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w/w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w/w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w/w tebipenem pivoxil HBr, 5-25% w/w of a diluent, 0.5 to 5% w/w of a glidant, 0.5 to 5% w/w of a lubricant, and optionally 0.5 to 5% w/w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.

    Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
    6.
    发明授权
    Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use 有权

    公开(公告)号：US10889587B2

    公开(公告)日：2021-01-12

    申请号：US16483989

    申请日：2018-02-06

    Applicant: SPERO THERAPEUTICS, INC.

    Inventor： Akash Jain ,  Evan Hecker ,  Richard Edwards ,  Thierry Bonnaud

    IPC: C07D477/20 ,  A61K45/06 ,  A61P31/04

    Abstract: The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

Patent Agency Ranking